Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 18/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | MMP15 | P51511 | 1/20 | 0.44 |
| ▸ | MMP16 | P51512 | 1/20 | 0.44 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139317 | 0.92 | GHSR (0.57) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3075433 | 0.92 | GHSR (0.60) | GHSR | |
| SCHEMBL3075932 | 0.89 | GHSR (0.63) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3075509 | 0.89 | GHSR (0.62) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3071321 | 0.89 | GHSR (0.53) | GHSR | |
| SCHEMBL3075598 | 0.88 | GHSR (0.59) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3069855 | 0.88 | GHSR (0.52) | GHSR | |
| SCHEMBL3071326 | 0.88 | GHSR (0.52) | GHSRMMP1MMP2MMP7MMP9 | |
| SCHEMBL3069228 | 0.88 | GHSR (0.61) | GHSRMMP2MMP9MMP12MMP14 | |
| SCHEMBL3076015 | 0.88 | GHSR (0.61) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | GHSR 351/4885MMP1 4870/4885MMP2 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.